Dynavax Technologies (Dynavax Technologies) GF Value

: $8.31 (As of Today)

View and export this data going back to 2004. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-19), Dynavax Technologies's share price is $11.35. Dynavax Technologies's GF Value is $8.31. Therefore, Dynavax Technologies's Price-to-GF-Value for today is 1.37.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Dynavax Technologies is Significantly Overvalued.

Dynavax Technologies (NAS:DVAX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Dynavax Technologies's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	11.35	/	8.31
	=	1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dynavax Technologies GF Value Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (Dynavax Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Executives

Robert Janssen	officer: Chief Medical Officer and VP	C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack	officer: Senior Vice President	39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess	officer: Principal Accounting Officer	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer	officer: Co-President and Senior VP	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald	officer: SVP and CFO	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman	officer: Chief Science Officer and VP	C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach	officer: VP, CBO, and General Counsel	1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063